GPER1 and heart failure: The importance of NLRP3 upregulation in GPER KO-induced heart failure was further confirmed in an in vivo study showing that, compared with vehicle-treated KO mice, 8 weeks of treatment with a NLRP3 inhibitor, MCC950 (10 mg/kg, i.p., 3 times per week), significantly limits hypertrophic remodeling and improves LV systolic and diastolic function (22).